Enveda, a Colorado-based biotech, reported Phase Ib results for ENV-294 in moderate-to-severe atopic dermatitis, with interim findings from nine adult patients showing a mean 85% reduction in Eczema Area and Severity Index (EASI) scores at Day 42. The open-label, single-arm study enrolled patients who had prior systemic therapy exposure, and the data were released April 1, 2026.
At Day 28, the end of the 28-day dosing period, patients receiving 800 mg oral ENV-294 once daily achieved a mean 68% EASI reduction from baseline. By Day 42 — 14 days after treatment cessation — that figure deepened to 85%. At that same timepoint, 100% of patients achieved EASI-50, 78% achieved EASI-75, and 56% reached EASI-90. In addition, 44% of patients achieved a vIGA-AD score of 0 or 1, including two patients with complete skin clearance; one of those two was a confirmed non-responder to an IL-4R pathway biologic. Improvements in itch, measured by PP-NRS and SCORAD, were also reported, though no specific numerical values for those endpoints were disclosed. No serious or severe adverse events occurred, no treatment-related adverse events were reported, and no patients discontinued. Laboratory parameters, vital signs, and ECGs showed no clinically meaningful changes, the company said.
Within a broader Phase II study, the Phase Ib part enrolled nine adults with moderate-to-severe atopic dermatitis and was designed as an open-label, uncontrolled, single-arm trial; no placebo group was included and no randomization was described. The 800 mg dose was the highest tested in the preceding Phase Ia study. Efficacy data beyond the 42-day observation window were not reported, and the study was not powered or designed to establish efficacy. The data remain from a subset of nine patients, and the absence of a control arm limits interpretation of the clinical findings. Biomarker data indicating modulation of Th2, Th17, and Th1 pathways were reported qualitatively, but no specific numerical biomarker values were disclosed.
ENV-294 is described by Enveda as a non-degrading molecular glue, or "LOCKTAC", intended to reconfigure cellular immunity to chronic inflammation rather than blocking individual cytokines. In moderate-to-severe atopic dermatitis, dupilumab (Dupixent), an IL-4/IL-13 receptor antagonist biologic, achieved EASI-75 in approximately 38% of patients at Week 16 in its pivotal SOLO trials, while upadacitinib (Rinvoq), an oral JAK1 inhibitor, achieved EASI-75 in approximately 70% of patients at Week 16 in the Measure Up 1 study — though both carry distinct safety monitoring requirements. Cross-trial comparisons are limited by differences in study design, duration, and patient populations.
Spot something wrong? Report an issue with this article